Industry Monthly
June 2026 Industry Monthly
A monthly digest of policy, market, and technology developments across the pharmaceutical industry, based on public sources.
Policy & Pricing
Fiscal council calls for full implementation of the FY2027 price revision
On June 26 the Fiscal System Council issued its recommendations on strengthening national capacity and fiscal management. On the FY2027 drug-price revision, it states the revision "should be fully implemented" — not narrowed in scope or pricing rules merely because it falls in an odd-numbered year — on the same footing as even-year revisions. It also calls for a roadmap to raise cost-sharing for patients aged 70 and over to 30% in principle.
Source: MOF, Fiscal System CouncilExpert's View
Full implementation of the off-year revision is consistent as fiscal logic. But if the end of relentless price cuts is supply halts and withdrawals, the patients whose burden was supposedly eased end up losing access to the medicine itself.
Growth-strategy council targets world-level growth for the patented-drug market
On June 24 the government convened the fifth Japan Growth Strategy Council jointly with the Council on Economic and Fiscal Policy, presenting a draft public-private investment roadmap across 17 strategic fields. For drug discovery and advanced medicine, it sets a goal of growth in Japan's patented-drug market on par with global growth, so the domestic market is no longer outmatched by markets abroad. It also flags the risk that U.S. most-favored-nation pricing is clouding launch strategies and could leave clinical trials un-run in Japan.
Source: Cabinet Secretariat, Japan Growth Strategy CouncilExpert's View
In the same month, the fiscal council said cut prices to the bone while the growth council said grow the market to world levels. If politics passes that contradiction downstream without resolving it, the people who absorb it are the patients waiting for new drugs.
Draft policy framework confirms an FY2027 drug-price revision
On June 30 the government presented the draft of its Basic Policy 2026 to the Council on Economic and Fiscal Policy. It states that an FY2027 drug-price revision will be carried out in the interest of drug-discovery innovation, stable supply, and easing the public burden, and calls for review of the cost-effectiveness assessment system and of how innovative new drugs are valued, including pricing during the patent period. It also flags a possible expansion of the rollback of insurance coverage for OTC-equivalent drugs (cabinet approval came in July).
Source: Cabinet Office, Council on Economic and Fiscal PolicyExpert's View
The draft sets "innovation" and "easing the burden" side by side, but listing them together is not yet a policy. For patients, whether the drug they will need next even launches in Japan hangs on how sharply that single sentence gets resolved.
June generic listings: 39 products across 10 first-time molecules
Supplementary generic listings took effect on June 12, covering 39 products across 10 molecules going generic for the first time. The antihistamine Bilanoa (bilastine) drew 13 products from 10 manufacturers, alongside listings for Desalex, Revolade, and Fycompa.
Source: CloseDiExpert's View
Generic substitution lowers what patients pay out of pocket, but ten manufacturers crowding into a single molecule cuts both ways for supply stability. Being able to make a drug cheaply is not the same as being able to keep delivering it without interruption.
Market & Business
U.S. price cuts raise drug-loss concerns in Japan
Nikkei reported on June 13 that under U.S. most-favored-nation drug pricing, accepting a low price in Japan can force price cuts in the U.S. market as well — leading major pharmaceutical companies to hint at skipping Japanese launches. Government materials from the Growth Strategy Council likewise warn the policy could leave clinical trials un-run in Japan.
Source: NikkeiExpert's View
Drug loss is the moment a conversation about price turns into a question of whether the medicine reaches the patient at all. Now that Japan's prices have become a variable in global pricing strategy, the cost of driving them down is increasingly borne not by companies but by patients.
Takeda names Julie Kim chief executive
Julie Kim became president and CEO of Takeda Pharmaceutical at the close of its 150th annual shareholders' meeting on June 24, succeeding Christophe Weber after his twelve years at the helm. Kim joined Takeda through the 2019 Shire acquisition and has led its plasma-derived therapies and U.S. businesses.
Source: Iyaku TsushinshaExpert's View
A leadership change at Japan's largest drugmaker signals where Japanese drug discovery will place its bets. From a patient's vantage point, who sits at the top matters less than which disease areas the resources flow toward — that is what decides whether a treatment exists for them.
GNI to acquire Ayumi Pharmaceutical for about ¥45 billion
GNI Group announced on June 5 that it will take full ownership of Ayumi Pharmaceutical Holdings, maker of the analgesic Calonal. The equity purchase is around ¥45 billion, with the total including debt seen exceeding ¥100 billion. GNI is buying out three shareholders — Blackstone, Toho Holdings, and Hisamitsu — and will use Ayumi's sales network to expand its own products.
Source: NikkeiExpert's View
A staple analgesic like Calonal earns thin margins yet underpins everyday clinical care. With ownership moving from a fund to an operating company, the question is whether continuity of supply now outranks a short-horizon return.
Otsuka completes acquisition of Transcend Therapeutics
Otsuka Pharmaceutical announced on June 15 that it had completed its acquisition of U.S. biotech Transcend Therapeutics via subsidiary Otsuka America. The all-share purchase is valued at $700 million, with up to $525 million more tied to sales milestones. Transcend is developing TSND-201 for PTSD, now in Phase 3.
Source: Otsuka PharmaceuticalExpert's View
PTSD has few effective pharmacological options, and patients have long been left waiting. Large capital moving into psychiatry is itself a sign that conditions once pushed down the priority list are being revalued.
May drugstore sales reach ¥836.3 billion, up 7.3%
Preliminary trade statistics released by METI on June 29 put May drugstore sales at ¥836.3 billion, up 7.3% year on year. Dispensed pharmaceuticals came to ¥83.1 billion (+6.8%) and OTC drugs to ¥87.7 billion (+3.4%), while beauty care (+10.7%) and household goods (+11.5%) drove the growth. Store count rose to 20,741.
Source: Ryutsuu News (METI Current Survey of Commerce)Expert's View
Dispensing is growing, yet cosmetics and household goods are what drive the top line. If drugstores are to serve as a community's first health touchpoint, the gap between what sells the floor and the role we want them to play is the thing to close.
Products & Technology
Eight new molecular entities approved, including Japan's first BTK inhibitor for urticaria
Eight new molecular entities won marketing approval on June 19. They include Rapsido (remibrutinib), Japan's first BTK inhibitor for chronic spontaneous urticaria; Wayrilz (rilzabrutinib), a first BTK inhibitor for immune thrombocytopenia; and Etcama (camizestrant), a next-generation SERD for HR-positive/HER2-negative breast cancer. Twenty-one supplementary indications were approved the same day, including an expansion of Wegovy into MASH (metabolic dysfunction-associated steatohepatitis).
Source: Shinyaku Joho OnlineExpert's View
Chronic urticaria is easily dismissed as non-life-threatening, yet the itching and disrupted sleep steadily erode quality of life. What it means for patients who have failed existing therapies to finally have a new mechanism available is not something an approval count can show.
Radiotherapy planning AI wins a first-of-its-kind Class III approval
Airato announced on June 26 that its radiotherapy planning AI, RatoAI, received marketing approval dated June 24 — the first Class III software-as-a-medical-device approval granted to a Japanese startup. The system assists contouring of more than 100 normal organs on CT images and uses a machine-learning model to infer dose distribution in support of treatment planning.
Source: Airato (PR TIMES)Expert's View
Radiotherapy planning still leans on skilled manual work, with contouring alone sometimes taking hours. If AI levels the quality of that planning, it could narrow the degree to which a patient's outcome depends on which hospital they happen to reach.
* This report is edited by Yap Inc. based on publicly available sources. “Expert’s View” reflects the perspective of CEO Masaya Yamamoto (a NewsPicks Expert). Please refer to the original source for details on each item.
View More News